Insulinoma pathophysiology: Difference between revisions
No edit summary |
|||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Insulinoma may occur as part of other genetic syndromes such as [[multiple endocrine neoplasia type 1]] and [[von Hippel-Lindau syndrome]]. On microscopic histopathological analysis, solid or gyriform patterns, usually without glands are characteristic findings of insulinoma. | Insulinoma may occur as part of other genetic syndromes such as [[multiple endocrine neoplasia type 1]] and [[von Hippel-Lindau syndrome]]. On microscopic histopathological analysis, solid or gyriform patterns, usually without glands are characteristic findings of insulinoma. | ||
==Microscopic Pathology== | ==Microscopic Pathology== |
Revision as of 17:37, 17 August 2017
Insulinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Insulinoma pathophysiology On the Web |
American Roentgen Ray Society Images of Insulinoma pathophysiology |
Risk calculators and risk factors for Insulinoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]Parminder Dhingra, M.D. [3]
Overview
Insulinoma may occur as part of other genetic syndromes such as multiple endocrine neoplasia type 1 and von Hippel-Lindau syndrome. On microscopic histopathological analysis, solid or gyriform patterns, usually without glands are characteristic findings of insulinoma.
Microscopic Pathology
On microscopic histopathological analysis characteristic findings of insulinoma are:
- Solid or gyriform patterns, usually without glands
Overview
- It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
- [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
- Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
- [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
- The progression to [disease name] usually involves the [molecular pathway].
- The pathophysiology of [disease/malignancy] depends on the histological subtype.
Pathophysiology
Pathogenesis
- Insulinoma is a rare benign pancreatic neuroendocrine tumor that arises from B islet cells, which are cells that are normally involved in the production of insulin. Few insulinomas can also produce other hormones such as Serotonin, gastrin, ACTH, glucagon, and somatostatin [1]
- They are usually small(90%), sporadic(90%), solitary(90%) and benign(90%) tumors.
- It usually occur s pordically but 10% are found to be associated with MEN 1 syndrome.[2]Those associated with the MEN1 syndrome are usually malignant and higher recurrence rate(21% at 10 and 20 years) than in those without MEN 1 (5% at 10 and 7% at 20 years). [3].
- It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Inhibitors of mTOR(rapamycin) or dual PI3K/mTOR(NVP-BEZ2235)thus have become new drugs for treating insulinoma. An oral mTOR inhibitor, Everolimus, make better glycemic control in people having insulinoma.[4] The pathway will give more possibilities for medical treatment.[5]
- The progression to hypoglycemia is actually because of decreased glucose synthesis rather than increased use due to the direct effect of insulin on the liver.[7]
Genetics
- Insulinoma is transmitted in an autosomal dominant pattern when it is associated with MEN 1 syndrome.
- Genes involved in the pathogenesis of insulinoma include MEN1gene. Loss of heterozygosity of MEN1 gene takes place on chromosome 11q13[8]
Associated Conditions
- Other pancreatic neuroendocrine tumors like gastrinoma, glucagonoma, VIPoma, somatostatinoma
- MEN 1[3]
- von Hippel-Lindau
- Neurofibromatosis type 1
Gross Pathology
- On gross pathology insulinomas have a red brown appearance, are usually small and solitary tumors. Although there is a case report of a large(9cm), pedunculated and weighing more than 100g.[9]
- Almost all insulinomas are present throughout the pancreas and extrapancreatic ones causing hypoglycemia are rare(<2%)[10]
Microscopic Pathology
- On microscopic histopathological analysis, [feature2], and [feature3] are characteristic findings of insulinoma.
-
Histopathology of pancreatic endocrine tumor (insulinoma). H&E stain[11]
-
Histopathology of pancreatic endocrine tumor (insulinoma)[11]
-
Histopathology of pancreatic endocrine tumor (insulinoma). Chromogranin A immunostain[11]
-
Histopathology of pancreatic endocrine tumor (insulinoma). Insulin immunostain[11]
References
- ↑ AlJadir, Saadi (2015). "Insulinoma: Literature's Review (Part 1)". Endocrinology&Metabolism International Journal. 2 (3). doi:10.15406/emij.2015.02.00025. ISSN 2473-0815.
- ↑ Callender GG, Rich TA, Perrier ND (2008). "Multiple endocrine neoplasia syndromes". Surg Clin North Am. 88 (4): 863–95, viii. doi:10.1016/j.suc.2008.05.001. PMID 18672144.
- ↑ 3.0 3.1 Service FJ, McMahon MM, O'Brien PC, Ballard DJ (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clin Proc. 66 (7): 711–9. PMID 1677058.
- ↑ Kulke MH, Bergsland EK, Yao JC (2009). "Glycemic control in patients with insulinoma treated with everolimus". N Engl J Med. 360 (2): 195–7. doi:10.1056/NEJMc0806740. PMID 19129539.
- ↑ Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L; et al. (2012). "Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis". J Surg Oncol. 106 (8): 972–80. doi:10.1002/jso.23176. PMID 22711648.
- ↑ Cao, Yanan; Gao, Zhibo; Li, Lin; Jiang, Xiuli; Shan, Aijing; Cai, Jie; Peng, Ying; Li, Yanli; Jiang, Xiaohua; Huang, Xuanlin; Wang, Jiaqian; Wei, Qing; Qin, Guijun; Zhao, Jiajun; Jin, Xiaolong; Liu, Li; Li, Yingrui; Wang, Weiqing; Wang, Jun; Ning, Guang (2013). "Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1". Nature Communications. 4. doi:10.1038/ncomms3810. ISSN 2041-1723.
- ↑ Rizza, R. A.; Haymond, M. W.; Verdonk, C. A.; Mandarino, L. J.; Miles, J. M.; Service, F. J.; Gerich, J. E. (1981). "Pathogenesis of Hypoglycemia in Insulinoma Patients: Suppression of Hepatic Glucose Production by Insulin". Diabetes. 30 (5): 377–381. doi:10.2337/diab.30.5.377. ISSN 0012-1797.
- ↑ Shin JJ, Gorden P, Libutti SK (2010). "Insulinoma: pathophysiology, localization and management". Future Oncol. 6 (2): 229–37. doi:10.2217/fon.09.165. PMC 3498768. PMID 20146582.
- ↑ Mittendorf EA, Liu YC, McHenry CR (2005). "Giant insulinoma: case report and review of the literature". J Clin Endocrinol Metab. 90 (1): 575–80. doi:10.1210/jc.2004-0825. PMID 15522939.
- ↑ Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K (2013). "Diagnosis and management of insulinoma". World J. Gastroenterol. 19 (6): 829–37. doi:10.3748/wjg.v19.i6.829. PMC 3574879. PMID 23430217.
- ↑ 11.0 11.1 11.2 11.3 Neuroendocrine tumour of the pancreas. Libre Pathology. http://librepathology.org/wiki/index.php/Neuroendocrine_tumour_of_the_pancreas